Authors: Brian Wu, MD candidate, Keck School of Medicine, Los Angeles, USA. DermNet New Zealand Editor in Chief: Hon A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy editor: Maria McGivern. March 2017.
A psychodermatological disorder is a condition that affects both the skin and the mind. It has both physical and psychosocial components. In these cases, effective management of the skin disorder must take into account the psychological/psychiatric factors.
Researchers use the term ‘neuro-immuno-cutaneous system’ (NICS) to describe this relationship.
Classification of psychodermatological disorders
Psychodermatological disorders may be divided into three categories:
Psychophysiological disorders, where emotional stress can exacerbate symptoms; an example is psoriasis
Primary psychological disorders, where the psychological condition results directly in cutaneous symptoms, such as delusions of parasitosis
Secondary psychological disorders, where a disfiguring skin condition can lead to psychological problems such as depression.
Assessment tools for psychodermatological disorders include the following questionnaires:
The Person-Centered Dermatology Self-Care Index (PeDeSI)
The Psoriasis Disability Index (PDI)
The Dermatitis Family Impact (DFI) questionnaire.
Pharmacological options for psychodermatological disorders
The pharmacological treatment options for the psychological/psychiatric factors involved in psychodermatological disorders depend on the type of disorder being treated. They can include:
Anti-anxiety agents, such as benzodiazepines or selective serotonin reuptake inhibitors (SSRIs)
Antihistamines including hydroxyzine, beta-blockers such as propranolol, and antiepileptic drugs eg, pregabalin
Antidepressants are used if depression is exacerbating a dermatological condition (note: tricyclic antidepressants also have antihistaminic properties).